1985
ESTROGEN REPLACEMENT THERAPY AND FIBROCYSTIC BREAST DISEASE IN POSTMENOPAUSAL WOMEN1
BERKOWITZ G, KELSEY J, HOLFORD T, LIVOLSI V, MERINO M, BECK G, ORT S, O'CONNOR T, WHITE C. ESTROGEN REPLACEMENT THERAPY AND FIBROCYSTIC BREAST DISEASE IN POSTMENOPAUSAL WOMEN1. American Journal Of Epidemiology 1985, 121: 238-245. PMID: 4014118, DOI: 10.1093/oxfordjournals.aje.a113994.Peer-Reviewed Original ResearchConceptsFibrocystic breast diseaseEstrogen replacement therapyBreast diseaseReplacement therapyPostmenopausal womenHospital-based case-control studyMedical care utilizationPossible risk factorsCase-control studyDuration of useOdds of diseasePostmenopausal women1Care utilizationMenopausal estrogensExcess oddsRisk factorsSurgical conditionsTherapyDiseasePositive associationMore yearsWomenOddsAssociationEstrogen
1984
Exogenous hormone use and fibrocystic breast disease by histopathologic component
Berkowitz G, Kelsey J, Livolsi V, Merino M, Holford T, Hildreth N, Ort S, O'Connor T, White C. Exogenous hormone use and fibrocystic breast disease by histopathologic component. International Journal Of Cancer 1984, 34: 443-449. PMID: 6490201, DOI: 10.1002/ijc.2910340403.Peer-Reviewed Original ResearchConceptsFibrocystic breast diseaseEstrogen replacement therapyBreast diseaseGross cystsReplacement therapyHospital-based case-control studyExogenous hormone useOral contraceptive usePost-menopausal womenCase-control studyPostmenopausal womenPremenopausal womenHormone useOral contraceptivesEpithelial atypiaControl womenPapillary hyperplasiaBiopsy specimensFibrocystic lesionsSurgical conditionsContraceptive useHistopathologic componentsWomenIncreased occurrenceDiseaseORAL CONTRACEPTIVE USE AND FIBROCYSTIC BREAST DISEASE AMONG PRE- AND POSTMENOPAUSAL WOMEN1
BERKOWITZ G, KELSEY J, LIVOLSI V, HOLFORD T, MERINO M, ORT S, O'CONNOR T, GOLDENBERG I, WHITE C. ORAL CONTRACEPTIVE USE AND FIBROCYSTIC BREAST DISEASE AMONG PRE- AND POSTMENOPAUSAL WOMEN1. American Journal Of Epidemiology 1984, 120: 87-96. PMID: 6741927, DOI: 10.1093/oxfordjournals.aje.a113878.Peer-Reviewed Original ResearchConceptsFibrocystic breast diseaseOral contraceptive useBreast diseaseOral contraceptivesContraceptive useHospital-based case-control studyOral contraceptive exposureGeneral surgical serviceCase-control studyLong-term useContraceptive exposurePostmenopausal women1Postmenopausal womenPremenopausal womenCystic diseaseStudy groupSurgical servicesDecreased frequencyPast usersDiseaseIncreased occurrenceWomenContraceptivesNegative associationAssociation
1983
Oral Contraceptive Use and Fibrocystic Breast Disease With Special Reference to Its Histopathology23
Pastides H, Kelsey J, LiVolsi V, Holford T, Fischer D, Goldenberg I. Oral Contraceptive Use and Fibrocystic Breast Disease With Special Reference to Its Histopathology23. Journal Of The National Cancer Institute 1983, 71: 5-9. PMID: 6575209, DOI: 10.1093/jnci/71.1.5.Peer-Reviewed Original ResearchConceptsOral contraceptive useFibrocystic breast diseaseOral contraceptivesContraceptive useBiopsy specimensBreast diseaseHospital-based case-control studyCase-control studyHigh atypiaEpithelial atypiaGross cystsHistopathologic characteristicsFibrocystic diseaseAtypiaContraceptivesDiseaseMicroscopic cystsCystsNew HavenSimilar patternPapillomatosisHistopathologySpecial referenceCasesControl
1982
A CASE-CONTROL STUDY OF CANCER OF THE ENDOMETRIUM
KELSEY J, LIVOLSI V, HOLFORD T, FISCHER D, MOSTOW E, SCHWARTZ P, O'CONNOR T, WHITE C. A CASE-CONTROL STUDY OF CANCER OF THE ENDOMETRIUM. American Journal Of Epidemiology 1982, 116: 333-342. PMID: 7114042, DOI: 10.1093/oxfordjournals.aje.a113417.Peer-Reviewed Original ResearchConceptsCase-control studyEndometrial cancerHospital-based case-control studyEstrogen replacement therapyOral contraceptivesDecreased riskReplacement therapyElevated riskOlder ageCancerStatistical significanceWomenRiskNulliparityOverweightMenopauseEndometriumPregnancyContraceptivesTherapyEpidemiology